Compare BTBD & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTBD | ENSC |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 8.2M |
| IPO Year | 2019 | 2017 |
| Metric | BTBD | ENSC |
|---|---|---|
| Price | $1.52 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.08 |
| AVG Volume (30 Days) | 9.8K | ★ 278.3K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.24 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,823,472.00 | $5,066,650.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.03 | $0.23 |
| 52 Week High | $2.48 | $2.16 |
| Indicator | BTBD | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 49.44 |
| Support Level | $1.10 | $0.39 |
| Resistance Level | $1.92 | $0.44 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 39.66 | 66.38 |
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.